(Q36390841)

13 August 2017

1 reference

title

Topiramate for the treatment of epilepsy and other nervous system disorders (English)

1 reference

13 August 2017

author

Lawrence James Hirsch

series ordinal

3

object named as

Lawrence J Hirsch

1 reference

13 August 2017

Leonie van Passel

1

1 reference

13 August 2017

Hiba Arif

series ordinal

2

1 reference

13 August 2017

language of work or name

1 reference

1 January 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

19-31

1 reference

The cost of epilepsy in the United States: an estimate from population-based clinical and survey data

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Effect of topiramate on the anticonvulsant activity of conventional antiepileptic drugs in two models of experimental epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Effects of topiramate in two models of genetically determined generalized epilepsy, the GAERS and the Audiogenic Wistar AS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate increases cerebral GABA in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate inhibits trigeminovascular neurons in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Children with focal sharp waves: clinical and genetic aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate: a review of preclinical, pharmacokinetic, and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Pharmacokinetic interactions of topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Effect of antiepileptic drug comedication on lamotrigine clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate pharmacokinetics in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Teratogenicity of antiepileptic drugs: analysis of possible risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate titration and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Low-dose topiramate in adults with treatment-resistant partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

A pilot study of topiramate in the treatment of infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate in migraine prevention: results of a large controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate for migraine prevention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate relieves idiopathic and symptomatic trigeminal neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Glutamate-mediated transmission, alcohol, and alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

A pilot trial of topiramate for the treatment of cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

The mechanism of neuroprotection by topiramate in an animal model of epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate blocks perinatal hypoxia-induced seizures in rat pups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Renal handling of citrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate increases biochemical risk of nephrolithiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate-induced metabolic acidosis: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate and metabolic acidosis in infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate in migraine prevention: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate as an adjunctive treatment in migraine prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate in the prophylactic treatment of cluster headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

The role of the glutamatergic system in alcohol addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

Double-Blind, Placebo-Controlled, Lamotrigine in Treatment-Resistant Generalised Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.19

21 January 2018

Identifiers

DOI

10.1586/14737175.6.1.19

1 reference

13 August 2017

1 reference